Regorafenib in gastrointestinal stromal tumors.

Item

http://www.wikidata.org/entity/Q39141806

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Regorafenib in gastrointestinal stromal tumors.

@en

Regorafenib in gastrointestinal stromal tumors.

@nl

type

Item

label

Regorafenib in gastrointestinal stromal tumors.

@en

Regorafenib in gastrointestinal stromal tumors.

@nl

prefLabel

Regorafenib in gastrointestinal stromal tumors.

@en

Regorafenib in gastrointestinal stromal tumors.

@nl

P1476

Regorafenib in gastrointestinal stromal tumors.

@en

P2093

Bhawna Sirohi

http://www.w3.org/2001/XMLSchema#string

Deepa Susan Philip

http://www.w3.org/2001/XMLSchema#string

Shailesh V Shrikhande

http://www.w3.org/2001/XMLSchema#string

P2860

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Gastrointestinal stromal tumors: pathology and prognosis at different sites.

P304

1581-1587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.101

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264988763

http://www.w3.org/2001/XMLSchema#string

P698

25145429

http://www.w3.org/2001/XMLSchema#string